![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24593-24601, August 27, 1999
,
,
From the
Departments of Medicine and Physiology,
University of Toronto, Toronto, Ontario M5S 1A8, Canada and the
§ Department of Physiology, University of British Columbia,
Vancouver V6T 1Z3, British Columbia, Canada
| |
ABSTRACT |
|---|
|
|
|---|
Glucose-dependent insulinotropic
polypeptide (GIP) is a gastrointestinal hormone involved in the
regulation of insulin secretion. In non-insulin-dependent
diabetes mellitus insulin responses to GIP are blunted, possibly due to
altered signal transduction or reduced receptor number. Site-directed
mutagenesis was used to construct truncated GIP receptors to study the
importance of the carboxyl-terminal tail (CT) in binding, signaling,
and receptor internalization. Receptors truncated at amino acids 425, 418, and 405, expressed in COS-7 or CHO-K1 cells, exhibited similar binding to wild type receptors. GIP-dependent cAMP
production with the 405 mutant was decreased in COS-7 cells. Maximal
cAMP production in CHO-K1 cells was reduced with all truncated forms. Binding was undetectable with a receptor truncated at amino acid 400;
increasing tail length by adding 5 alanines restored binding and
signaling. Mutants produced by alanine scanning of residues 394-401,
adjacent to transmembrane domain 7, were all functional. CT truncation
by 30 or more amino acids, mutation of serines 426/427, singly or
combined, or complete CT serine knockout all reduced receptor
internalization rate. The majority of the GIP receptor CT is therefore
not required for signaling, a minimum chain length of ~405 amino
acids is needed for receptor expression, and serines 426 and 427 are
important for regulating rate of receptor internalization.
Incretins are peptide hormones released from the gastrointestinal
tract into the circulation in response to a meal that potentiate glucose-stimulated insulin secretion. There are two established incretins: gastric inhibitory polypeptide/glucose-dependent
insulinotropic polypeptide
(GIP)1 and the truncated
forms of glucagon-like peptide-1 (GLP-1). In non-insulin-dependent diabetes mellitus (NIDDM), the
incretin effect following oral glucose is reduced or absent (1, 2), and
the insulin response to intravenously administered GIP, but not GLP-1,
has been reported to be severely blunted (2, 3). Possible explanations
for a decreased responsiveness to GIP include a defective
signal-transduction system and a reduction in the number of functional
pancreatic islet receptors due to altered expression, mutation, or
degree of desensitization and/or internalization. To elucidate which of
these could be involved in reduced responsiveness, it is necessary to
develop a greater understanding of the functional roles played by the
different structural components of the GIP receptor.
The receptor for GIP (4-6) is a member of the seven transmembrane
G-protein-coupled secretin-vasoactive intestinal peptide (VIP) family,
which includes the receptors for glucagon (7), glucagon-like peptide-1
(8), secretin (9), VIP (10), parathyroid hormone/parathyroid
hormone-related peptide (PTH/PTH-RP) (11), and calcitonin (12). The GIP
receptor has been shown to stimulate adenylyl cyclase in pancreatic
islet Extensive mutagenesis and chimeric receptor studies on the
The current studies were directed at defining the functional importance
of the CT of the rat GIP receptor. Carboxyl-terminally truncated
mutants of the receptor, produced by site-directed mutagenesis and
expressed in COS-7 and CHO-K1 cells, were studied with a view to
determining the effect of such mutations on ligand binding, stimulation
of G-protein-coupling to adenylyl cyclase, and ligand-induced internalization. In addition, studies were made on the effects of
partially replacing the CT of the shortest, inactive, mutant form with
a poly-alanine tail, and of mutating individual amino acids within the
proximal CT and all serines throughout the CT. It is concluded that the
majority of the GIP receptor CT is not required for signaling, a
minimum length of the tail, rather than the specific constituent amino
acids, is important for transport and insertion of the receptor into
the plasma membrane, and that Ser-426 and Ser-427 are involved in
receptor internalization.
Preparation of Rat GIP Receptor Truncation Mutants--
A
polymerase chain reaction strategy was used to generate truncation
mutants, utilizing the rat receptor cDNA (5) in the vector
pcDNA 3 (Invitrogen Co., San Diego, CA) as template. The 5'-sense
oligonucleotide primer corresponded to coding nucleotides
The respective primers corresponded to coding nucleotide bases:
1255-1276, 5'-CTACAAAGGCACCGCCCGGGGGGC-3'
(GIP-R-425); 1255-1236, 5'-CTACTGCCCCAGGTGCGGACGTG-3'
(GIP-R-418); 1216-1196, 5'-CTAGAGACGCAGACGGCGGATCTC-3' (GIP-R-405); 1198-1175,
5'-CTAGATCTCCGACTGTACCTCTTTGTTGAT-3' (GIP-R-400); 5'-CTATGCTGCTGCTGCTGCGATCTCCGACTGTACCTCTTTGTT3'
(GIP-R-400A5); and,
5'-CTATGCTGCTGCTGCTGCTGCTGCTGCTGCTACCTCTTTGTTGATGAAGCA-3' (GIP-R-396A9).
To examine more exactly the contribution of the most proximal residues
in the CT for receptor expression and G-protein coupling to adenylyl
cyclase, a double-stranded site mutagenesis strategy (Chameleon,
Stratagene, La Jolla, CA) was used to substitute individually the 8 residues (394-401) extending from the predicted seventh transmembrane
domain, with alanine residues. The resulting constructs were designated
GIP-R-K394A, GIP-R-E395A, GIP-R-V396A, GIP-R-Q397A, GIP-R-S398A,
GIP-R-E399A, GIP-R-I400A, and GIP-R-R401A. A deletion mutant lacking
residues 397-400 (GIP-R- Cell Transfection and Tissue Culture--
For transient
expression studies, COS-7 cells (3 × 106) were seeded
in 10-cm dishes (Becton Dickinson, Lincoln Park, NJ) and cultured in
Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Inc.)
supplemented with 10% fetal bovine serum (Cansera, Roxdale, Ontario).
Cells were transfected the following day with 5 µg (for cAMP assays)
or 10 µg (for binding assays) of either the wild type receptor
(GIP-R-455) cDNA or the appropriate mutant constructs by the
DEAE-dextran method as described previously (5). All plasmid DNAs were
prepared and purified using identical protocols, and the integrity of
the DNA was checked before transfection. To minimize variability in
day-to-day transfection efficiency, the various constructs for each set
of experiments were generally all transfected at the same time using
the same mixture. In all cases, the wild type receptor construct was
transfected as a control to allow correction for any small day-to-day
variations in transfection efficiency. 15 h after transfection,
the cells were passaged into either 6-well plates for cAMP studies, or
10-cm dishes for binding studies, and cultured for an additional
48 h. For production of permanent CHO-K1 cell lines expressing the
mutant GIP receptor cDNAs, cells were grown in DMEM/F12 media (Life
Technologies, Inc.) supplemented with 10% newborn calf serum (Cansera)
on 10-cm dishes until ~80% confluent. Cells were transfected with 10 µg of the appropriate cDNA using the CaPO4
co-precipitation method (5). As we have previously demonstrated that
cloned CHO-K1 cell lines obtained by pooling of clones, and maintained
under high stringency selection, express receptors at levels similar to
high level expressing clones (33), pooled CHO-K1 cell lines expressing
receptor constructs were isolated under high G418 (800 µg/ml)
selection. The wild type GIP-R-455 cDNA and stable line have been
described previously (5, 33).
Iodination of GIP and Binding Analysis--
Synthetic porcine
GIP (5 µg) was iodinated by the chloramine-T method, and the
125I-GIP further purified by reverse phase high pressure
liquid chromatography to a specific activity of 250-350 µCi/µg, as
described previously (5). Aliquots of tracer were lyophilized and
stored at Measurement of cAMP Production--
Receptor-expressing COS-7
cells (24 h after transfection) or CHO-K1 clones were passaged into
multiwell plates and cultured for an additional 48 h. Cells were
then washed in assay buffer containing 0.1% bovine serum albumin and
preincubated for 60 min, followed by a 30-min stimulation period with
GIP in the presence of 1 mM isobutylmethylxanthine
(Research Biochemicals International, Natick, MA), as described
previously (5, 33). Cells were extracted with ice-cold 70% ethanol,
and cAMP levels were measured by radioimmunoassay (Biomedical
Technologies, Stoughton, MA). Data were expressed as a percentage of
maximal levels observed with the wild type receptor (GIP-R-455) for
CHO-K1 cells, and picomoles of cAMP/well for COS-7 cells.
Internalization Studies--
Internalization of receptor-bound
ligand with wild type and truncated mutants was determined as described
by Widmann et al. (32). Briefly, cells were washed twice
with BB, and incubated in the presence of 125I-GIP (50,000 cpm) for 0-120 min (in triplicate), as indicated in Fig. 6. Binding
was stopped by two washes with ice-cold BB, followed by a 10-min wash
in ice-cold stripping buffer (150 mM NaCl, 50 mM glycine, pH 3.0) to remove surface bound tracer.
Acid-released 125I-GIP was collected, and the cells
solubilized in NaOH to determine internalized (acid resistant)
radioactivity. Nonspecific binding in both fractions was determined for
all time points by performing the identical experiments in the presence
of 1 µM unlabeled GIP and subtracting corresponding
values. The internalized 125I-GIP for each time point was
expressed as a percentage of total bound (acid resistant + acid strippable).
The internalization protocol used to study CHO-K1 cells stably
expressing receptor constructs with serine to alanine mutations in the
CT tail was based on that of Kallal et al. (34) and Petrou et al. (35). Cells were washed twice with BB at 37 °C,
and then incubated with 100 nM GIP for 0-60 min in
triplicate, as indicated in Fig. 9. Cells were then stripped of
non-internalized bound GIP by incubating with ice-cold stripping buffer
(as above) for 5 min, followed by two rinses with ice-cold BB. Cells
were then incubated with 125I-GIP (50,000 cpm) for 4 h
at 4 °C to prevent further internalization or recycling, washed
twice with ice-cold BB, and solubilized in 1 ml of NaOH for measurement
of cell-associated radioactivity. Nonspecific binding was measured in
the presence of 1 µM GIP. Binding data were then
expressed as percentage loss of surface receptors.
Data Analysis--
Data are expressed as means ± S.E.,
with the number of individual experiments presented in brackets.
Receptor binding and cAMP data were analyzed using the nonlinear
regression analysis program PRISM (GraphPad, San Diego, CA). All data
were tested for significance using analysis of variance analysis and,
when appropriate, by Dunnet's test for multiple comparisons as a
post-hoc test for significance.
Initially, a number of truncated forms of the GIP receptor were
constructed to examine the effect of progressive CT deletion on
receptor expression and G-protein activation. Receptors truncated at
residues 405, 418, and 425 exhibited high affinity binding in
competition binding experiments, similar to that seen in cells expressing the 455-amino acid wild type receptor (GIP-R-455) in both
transient studies with COS-7 cells (Figs.
1 and
2A) and in stable cell lines
generated in CHO-K1 cells (Fig. 2B, Table
I). Receptor expression levels, as
determined from Bmax values, indicated that
GIP-R-425 was expressed at least as efficiently as the wild type
receptor in both cell systems (121 ± 41% in COS-7; 126 ± 34% in CHO-K1) (Table I, Fig. 1). However, cells expressing GIP-R-418 exhibited 82 ± 17% (COS-7)/74 ± 16% (CHO-K1) and those
expressing GIP-R-405 36 ± 7% (COS-7)/29 ± 3% (CHO-K1) of
the maximal binding obtained with the wild type receptor. This
indicated that these truncated receptors were not as efficiently
expressed as the longer forms of the receptor at the plasma membrane
level. When the receptor was truncated at amino acid 400 (GIP-R-400) no
detectable 125I-GIP binding was observed. Cells expressing
GIP-R-425, GIP-R-418, and GIP-R-405 displayed similar binding
affinities to that of the full-length receptor in both COS-7 and CHO-K1
cells (Figs. 1 and 2; Table I).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
- and
-cells (13), islet tumor cells (14-16), and cell
lines transfected with pancreatic GIP receptor cDNAs (4-6).
However little is known regarding the specific components of the GIP
receptor, which are important for G-protein coupling or regulation of
desensitization and internalization.
-adrenergic and cholinergic receptors have indicated that all of the
intracellular loops of the seven transmembrane class of receptors can
play a role in G-protein binding, although the NH2 and COOH
termini of the third intracellular loop are considered to be of primary
importance for both G-protein binding and conferring specificity of
action (17-20). In recent studies on the GLP-1 receptor, which is very
closely related to that for GIP, sequences in the proximal and distal
portions of third intracellular loop were shown to be required for
coupling to Gs and adenylyl cyclase (21, 22). In contrast
to the extensive studies on the role of the intracellular loops in
G-protein-coupled receptor function, fewer functional studies on the
role of the COOH-terminal tail (CT) have been performed. This region
has been implicated in receptor desensitization and endocytosis
(23-26), and the NH2-terminal region of the
2-adrenergic receptor CT has been shown to be important for G-protein coupling (17). Additionally, the CT has been suggested to
play a role in routing transport of receptors to the plasma membrane
(27, 28) and restricting lateral movement within this membrane (17,
27). Studies on COOH-terminally truncated members of the secretin-VIP
family of receptors showed that reduction in the length of the CT
resulted in increased binding affinity of the PTH/PTH-RP (29),
calcitonin (30), and glucagon (31) receptors, whereas truncation
increased maximal cyclic (c)AMP production with the PTH/PTH-RP receptor
(29) but decreased production with the calcitonin receptor (30).
Recently phosphorylation of the CT of glucagon (26) and GLP-1 (32)
receptors has been shown to be required for both receptor
desensitization and sequestration and, in the case of the GLP-1
receptor, a series of three serine doublets exerts a
dose-dependent influence on both events (32).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
3 to +19
(5'-AGGATGCCCCTGCGGCTGTTGC-3'). Five 3'-antisense oligonucleotide primers were designed such that a stop codon (underlined) was introduced at desired positions to generate the mutants GIP-R-425, GIP-R-418, GIP-R-405 and GIP-R-400. Additionally, to examine the effect
of nonspecific sequence extension of the COOH-terminal tail, primers
were designed to extend residues 400 and 396 with poly-alanine tails of
5 and 9 residues. These are designated GIP-R-405A5 and
GIP-R-396A9.
QSEI), a mutant with cysteine 411 changed
to alanine (GIP-R-C411A), and a series of alanine substitution
mutations with CT serine residues mutated either individually (S398A,
S406A, S426A, S427A, S440A, S453A), in multiples (S426A/S427A) or
completely (S398A-S453A), were generated using the same methodology.
The identities of all mutants were confirmed by sequence analysis
(T7-Sequencing, Amersham Pharmacia Biotech).
20 °C until use. Binding analyses were performed as
described previously (5) with minor modifications. Briefly, COS-7 cells
were washed twice in binding buffer (BB; DMEM containing 20 mM HEPES and 0.1% bovine serum albumin, pH 7.4). Cells
(5 × 105/tube) were then incubated for 60 min at
37 °C with 125I-GIP (50,000 cpm), in the presence or
absence of unlabeled synthetic human GIP (Hukabel, Montreal, Canada or
Bachem, Torrance, CA) in a final volume of 200 µl. (It has been shown
previously that porcine and human GIP have identical binding affinities
for the rat GIP receptor (5).) After incubation, cell suspensions were centrifuged at 12,000 × g, the cells washed once in
ice cold BB, and cell-associated radioactivity in the pellet was
measured in a gamma counter. CHO-KI cells (1-5 × 105/well), plated 2 days before use in 24-well plates, were
washed twice at 4 °C in BB, consisting of DMEM/F12, 20 mM HEPES, and 0.1% bovine serum albumin, pH 7.4, and
incubated for 12-16 h at 4 °C with 125I-GIP (50,000 cpm) in the presence or absence of unlabeled GIP (each concentration
tested in triplicate). Cells were then washed twice in ice cold buffer,
solubilized with 0.1 M NaOH (1.0 ml), and transferred to
test tubes for counting of cell-associated radioactivity. Nonspecific
binding for both cell types was defined as that measured in the
presence of an excess of human GIP (1 µM), and specific
binding was expressed as a percentage of maximum binding
(%B/Bo).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (29K):
[in a new window]
Fig. 1.
Examination of GIP-R truncation mutations for
binding and cAMP stimulation in COS-7 cells. Receptor mutations
shown diagrammatically on the left were examined for their ability to
bind GIP in binding displacement assays (summarized as IC50
values and relative receptor expression (%Bmax
of GIP-R-455)), and for basal and GIP-stimulated (10 nM)
cAMP accumulation. Mean ± S.E.; n = three
independent experiments. Significant differences from GIP-R-455 in
Bmax (a) and cyclic AMP production
(b) p < 0.05. (nd, not
determined;
, nondetectable).

View larger version (17K):
[in a new window]
Fig. 2.
Binding analysis of GIP-R truncation mutants
in COS-7 and CHO-K1 cells. Binding of the GIP-R mutations were
examined for 125I-GIP binding in COS-7 cells expressing
truncated receptor mutants (A) and in CHO-K1 cells stably
expressing mutants (B). A summary of the results in CHO-K1
cells and statistical analyses is shown in Table I. COS-7 cell
statistics included in Fig. 1 are mean ± S.E.; n
3.
, GIP-R-455;
, GIP-R-400A5;
,
GIP-R-405;
, GIP-R-418;
, GIP-R-425.
Summary of binding data and cyclic AMP responses with carboxyl-terminal
tail-truncated forms of the GIP receptor expressed in CHO-K1 cells
The lack of detectable binding with GIP-R-400 suggested that either specific residues that had been deleted or a minimum CT tail length were important for receptor expression or binding. To determine whether the length of the tail was the determining factor, a sixth construct was prepared consisting of GIP-R-400 to which 5 alanine residues were added (GIP-R-400A5) to produce a similar chain length to GIP-R-405. Extension of the CT, with these nonspecific amino acid residues, restored binding in both transient and stable expression systems to levels approximating 50% of those seen for GIP-R-405 (Figs. 1 and 2; Table I). Although the level of expression of this receptor was low, compared with that of the wild type receptor, both COS-7 and CHO-K1 cells expressing GIP-R-400A5 specifically bound 125I-GIP with similar affinity to the wild type receptor (Figs. 1 and 2; Table I).
To examine the role of the more proximal residues of the CT, two
further constructions were designed, one with residues 397-405 replaced with 9 alanine residues (GIP-R-396A9), and the
other with residues 397-400 deleted (GIP-R-
QSEI). Neither of these constructs, when transfected into COS-7 or CHO-K1 cells, displayed 125I-GIP binding in competition experiments (Fig. 1; Table
I). These data suggested that the CT tail length was important for
efficient expression, but that specific residue(s) within the region
397-400 may also be functionally important.
To assess the influence of the CT on receptor coupling to G-proteins
and adenylyl cyclase, cAMP responses to GIP were determined in
transfected COS-7 and CHO-K1 cells. Maximal cAMP production was
greatest with GIP-R-455 in both systems. In COS-7 cells there were no
significant differences in cAMP accumulation between the truncated
receptor mutants GIP-R-425 (100 ± 6.5 pmol/well) or GIP-R-418
(93.4 ± 14.6 pmol/well) and the GIP-R-455 expressing cell line
(104 ± 17 pmol/well) (Fig. 1, p > 0.05, n = 3). However, COS-7 cells expressing GIP-R-405
displayed significantly decreased cAMP production (60.3 ± 12.7 pmol/well) in response to GIP (Fig. 1, n = 3, p < 0.05). As would be expected from the binding
experiments, GIP-R-400 did not respond to 10 nM GIP
(5.3 ± 0.7 pmol/well). Of particular importance was the
observation that extension of the receptor tail length to 405 amino
acids (GIP-R-400A5) restored cAMP production to levels
equivalent to GIP-R-405 (Fig. 1). Cells expressing the longer
poly-alanine construct (GIP-R-386A9) or the construct with
residues 397-400 deleted (GIP-R-
QSEI) failed to respond to GIP,
indicating that these receptors were either not expressed or that
regions important for G-protein coupling had been changed or deleted
(Fig. 1). In light of the binding data, the former is more likely.
Although similar results were obtained with the stable CHO-K1 cell
system, none of the truncated receptors displayed maximal cAMP
production equivalent to that seen with the GIP-R-455 cell line (Fig.
3; Table I). EC50 values for
GIP-R-418 and GIP-R-405 were decreased 4-6-fold (Table I, Fig. 3).
Surprisingly, although there was only a small decrease in the binding
affinity of GIP-R-400A5 for GIP (3.8 ± 0.2 nM) compared with the wild type receptor (2.2 ± 0.4 nM), there was a large increase in the EC50
value for cAMP production (1,163 ± 320 pM) compared
with the full-length receptor (69 ± 27 pM) (Fig. 3,
Table I). In agreement with the COS-7 cell experiments, CHO-K1 cells
transfected with GIP-R-396A9 were not responsive to GIP
stimulation with concentrations as high as 1 µM (Fig. 3,
Table I).
|
Given the fact that deletions of the receptor beyond residue 400 were
not tolerated with respect to expression, an alanine scan approach was
adopted to examine the importance of residues between 394 and 401 for
binding and G-protein coupling. These mutants were examined in COS-7
cells only (Figs. 4 and
5). All seven of the alanine-substituted
mutants displayed specific GIP binding and cAMP activation (Figs. 4 and
5). High affinity binding of 125I-GIP varied among the
other seven mutants, with IC50 values ranging from 0.7 to
3.0 nM. However, substitutions at positions Glu-395, Val-396, and Ile-400 resulted in receptor binding affinities increased 2-3-fold (Fig. 5). These same mutants were also expressed at
significantly reduced levels. GIP-R-K394A, GIP-R-Q397A, GIP-R-E399A,
and GIP-R-R401A displayed expression levels similar to GIP-R-455 (Fig.
5). Cyclic AMP responses with GIP-R-V396A were approximately 50% of
those with GIP-R-455 (Fig. 5).
|
|
Because the CT has been shown to influence sequestration of some
G-protein-coupled receptors, the effect of truncation on receptor
internalization was determined. All constructs that were expressed in
CHO-K1 cells were found to internalize over time as assessed by an
increase in the acid-resistant pool (Fig.
6). The wild type receptor clone
displayed a rapid increase in acid-resistant binding over time,
reaching maximal levels (64.9 ± 2.7% of total bound) within 120 min (Fig. 6, Table II). Maximum
internalization of the truncated receptors did not differ significantly
from that seen for the full-length GIP-R-455 receptor at 60-120 min.
Further incubation times, of up to 4 h, failed to reveal any
differences in maximal uptake among the different receptor constructs
in CHO-K1 cells (data not shown). Analysis of the initial linear uptake period showed that truncation of the tail to 425 or 418 amino acids
resulted in significant decreases in the rate of internalization over
the first 10 min, when compared with the wild type receptor (Fig. 6;
Table II). Further truncation of the CT by 50 amino acids (GIP-R-405)
partially restored the rate of uptake to wild type values, and uptake
of the construct GIP-R-400A5 was not significantly different from the wild type receptor.
|
|
To examine a possible role for specific CT amino acids in the
regulation of internalization, serine residues were targeted, because
phosphorylation of serine or threonine residues normally precedes
internalization of G-protein receptors (reviewed in Ref. 36). Each of
the serine residues in the CT was therefore mutated to alanine, either
singly or in multiples, and IC50 values, cyclic AMP
production, and internalization determined. Additionally, because Tseng
and Zhang (37), using truncation and alanine scan protocols similar to
those described in this study, recently provided evidence that
substitution of alanine for cysteine 411 completely ablated rat GIP
receptor desensitization, the effect of this mutation (GIP-R-C411A) on
receptor internalization was also examined. When expressed in COS-7
(Fig. 7) or CHO-K1 cells (Fig.
8, Table
III) none of the mutants differed
significantly from the wild type receptor with respect to binding
affinity, although mutation of serines 427 or 440 resulted in a
doubling of Bmax in transiently transfected
cells (Fig. 7). There were no significant differences in cAMP responses
to 10 nM GIP between the wild type and any of the mutant
receptors (Fig. 7). In agreement with the reduced internalization rate
observed with the CT truncated receptors, mutation of serine residues
426 or 427 to alanine resulted in decreases in initial rates of
internalization (Fig. 9, Table III).
GIP-R-S440A also demonstrated a decrease in its mean rate of
internalization, although this did not reach significance. Maximum
internalization of all three mutants was also reduced. A double mutant,
GIP-R-S426A/S427A, and a complete CT serine knockout mutant,
GIP-R-S398A-S453A in which serines 398, 406, 426, 427, 440, and 453 were all mutated to alanine residues, both exhibited reduced rates of
internalization and maximum internalization. The latter mutant was the
most profoundly affected with an internalization rate (0.75 ± 0.08%/min) only 46% of that of the wild type receptor (Table III).
Mutation of cysteine 411 to alanine had no effect on
internalization.
|
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The intracellular loops of the heptahelical receptors have been
implicated in G-protein recognition, coupling, and activation (19), but
there is no consensus as to the importance of the CT with regard to
these functions. Indeed, there appears to be considerable variability
in the importance of this region among the different G-protein-coupled
receptor types. For example, O'Dowd et al. (17) showed that
the NH2-terminal region of the human
2-adrenergic receptor CT was critical for coupling to
G-proteins and activation of adenylyl cyclase, whereas shortening of
the avian
-adrenergic receptor CT resulted in increased basal and agonist-stimulated cyclic AMP production, and reductions in agonist EC50 values (27). There have been few studies on the
importance of the CT of the secretin-VIP receptor family, and the only
relatively consistent finding has been an increase in affinity for
agonists with CT-truncated mutants, as reported for the PTH/PTH-RP
(29), calcitonin (30), and glucagon (31) receptors. In the case of the
GIP receptor, removal of up to 50 amino acids from the CT had no
significant effect on receptor binding affinity (IC50 values). This is similar to the human glucagon receptor, for which 62 of the amino acids in the CT were shown not to be required for binding
(26). Interestingly, however, with the GIP receptor, three separate
alanine substitution mutations within the proximal part of the CT
(E395A, V396A, I400A; Figs. 4 and 5) resulted in increased receptor
affinity. The cause of such increases is unclear, but one possibility,
suggested by Iida-Klein et al. (29) in studies on the
PTH/PTH-RP receptor, is that sequences in the CT lower the affinity of
the wild type receptor for agonist, and that structural changes to the
tail can reduce this effect. Changes in the interaction of the CT with
intracellular structural components could be involved (27).
It is evident from the GIP-induced cyclic AMP responses of the
truncation mutants that the majority of the COOH terminus of the
receptor is not essential for coupling to adenylyl cyclase, because a
mutant consisting of as few as 13 of the 63 amino acids was capable of
increasing cAMP production. The ability to remove a substantial portion
of the CT while retaining G-protein coupling is in agreement with
studies on other heptahelical receptors. In mutational analysis
experiments similar to those described here, progressive truncations of
the CT of the opossum (28) and human (38) PTH/PTH-RP receptors resulted
in no significant alterations in cyclic AMP production. Similarly,
removal of the distal two-thirds of the thyrotropin (39) and
luteinizing hormone/chorionic gonadotropin receptors (40) also resulted
in no change in ligand-induced activation of adenylyl cyclase. In
contrast, COOH-terminally truncated forms of both the rat PTH/PTH-RP
(29) and avian
-adrenergic (27) receptors were found to couple to
adenylyl cyclase with much higher efficacy than the wild type
receptors. Evidence was presented suggesting that the CT decreases
PTH/PTH-RP receptor affinity for Gs (29). The situation
with the PTH/PTH-RP is probably complicated, however, because pertussis
toxin-sensitive inhibitory effects of PTH on adenylyl cyclase were
observed only in wild type receptors, and it was proposed that the CT
plays a crucial role in interactions between receptors and inhibitory
G-proteins. In contrast to the PTH/PTH-RP receptor (29), decreased
maximal cAMP production was observed with truncated GIP receptors.
Although these decreases, as well as those in
Bmax, could have resulted from variability in
transfection efficiency, such a possibility was minimized by performing
all transfections for a set of experiments at the same time and using
the wild type construct as a control for transfection variability. As
discussed further below, a more likely explanation is a reduction in
plasma membrane expression levels. Interestingly, significantly lower
EC50 values (4-6-fold) were obtained for GIP-R-418 and
GIP-R-405. One possible interpretation of this result is that CT
shortening removes specific amino acids that induce less efficient
receptor-induced Gs coupling to adenylyl cyclase.
When the GIP receptor was truncated by 50 or more amino acids, the level of measurable receptor binding decreased dramatically. Truncation probably decreases the efficiency of receptor insertion in the plasma membrane, and the reduced maximal cyclase stimulation with GIP-R-405 reflects this reduced membrane expression. Cells transfected with the truncated mutant GIP-R-400 exhibited neither binding nor the ability to stimulate adenylyl cyclase. Although this could be due to either lack of receptor expression in the plasma membrane or dramatically reduced agonist binding to an expressed receptor, the former is more likely. There is probably a minimum length for efficient folding of a heptahelical receptor and its translocation from the endoplasmic reticulum and insertion into the plasma membrane. Such a lack of expression explains the inability to detect biological responses with these severely truncated mutants. Similar suggestions were made to explain the lack of detectable binding with extensively truncated PTH/PTH-RP receptors (28) and, more recently, with the human glucagon receptor (26). In the latter study, using CT mutation and alanine substitution techniques similar to those used here, it was shown conclusively that, as with the GIP receptor, the majority of the CT of the glucagon receptor could be deleted without compromising membrane insertion. Furthermore, a glucagon receptor mutant (RT410) equivalent to GIP-R-400 (apart from 1 less amino acid), was shown by immunostaining not to be expressed in the plasma membrane, whereas the mutant RT415, almost equivalent to GIP-R-405, was expressed. Unfortunately, the absence of a GIP receptor antibody precluded us from performing immunostaining studies similar to those of Buggy et al. (26). Taken together, the two studies suggest that a COOH-terminal peptide length of between 10 and 15 amino acids is necessary for membrane expression of this receptor sub-family. However, while the current studies were nearing completion, Tseng and Zhang (37) reported on similar CT-truncated rat GIP receptor mutants expressed in L293 cells. They were unable to detect binding with a mutant truncated at position 395, but found that a receptor truncated at amino acid 399 was expressed almost as efficiently as the wild type receptor and exhibited unchanged binding affinity. This is in contrast to our observation that binding with GIP-R-400 was undetectable. The reason for this discrepancy is unclear but could be related to differences in processing and targeting in the different cell lines. Further support for a minimal chain length of greater than 400 amino acids for receptor expression in CHO-K1 and COS-7 cells resulted from our CT extension studies.
Two possibilities were considered regarding the structure of the CT necessary for membrane expression. Either the specific sequence RLRL (amino acids 402-405) was required, or the chain length itself was the determining factor, and the specific amino acids were immaterial. A mutant receptor was therefore prepared, which extended the COOH-terminal chain with 5 alanines to produce a 405-amino acid protein (GIP-R-405A5). The level of receptor binding and the maximal level of cyclic AMP production with this receptor mutant were similar to those produced with GIP-R-405. However, there was a large increase in the EC50 value for cAMP production (1,163 ± 320 pM) compared with the full-length receptor (69 ± 27 pM) indicating that specific amino acids within the 400-405 region influence the efficiency of G-protein coupling. Interestingly, neither cells transfected with a GIP-R-396 construct extended with 9 alanine residues to a length of 405, nor those with a receptor in which amino acids 397-400 were deleted demonstrated any binding. This suggested that specific residues in the proximal part of the CT may be important for expression. Because it was not possible to test this hypothesis using the truncation paradigm, amino acids in the region 394-401 were individually mutated to alanines. Although all were expressed in COS-7 cells, the observation that the E395A, V396A, and I400A mutants were expressed with greatly reduced efficiency indicates that specific amino acids in the proximal part of the CT are important for expression.
It therefore appears that although there is considerable redundancy in the specific amino acids in the proximal CT of the GIP receptor that can allow G-protein coupling, the length of the tail and specific amino acids are both important for insertion into the plasma membrane. Because the proximal CT of the glucagon receptor (403-415 NKEVQSELRRRW) is almost identical to that of the GIP receptor (393-405 NKEVQSEIRRLRL), it is likely that a similar level of redundancy exists for this receptor. Specificity of G-protein binding in the secretin-VIP receptor family probably resides elsewhere within the intracellular domains, and evidence has been presented recently indicating a critical role for a single amino acid in the NH2-terminal portion of the IC-3 loop of the GLP-1 receptor for efficient coupling to adenylyl cyclase (21). This region is highly conserved among the secretin-VIP family and will probably prove to be equally important for GIP receptor activation. However, because IC-3 probably lies in close proximity to the proximal portion of the CT (17) the latter region may play a modulatory role.
The CT regions of a number of G-protein-coupled receptors, including
those for yeast
-mating factor (23), calcitonin (41), and GLP-1 (32)
have been shown to be phosphorylated on serine and threonine residues
and to be involved in both receptor desensitization and
internalization. There is variability, however, and the majority of the
CT of the PTH/PTH-RP (25) and
-adrenergic (42) receptors are not
required for receptor sequestration. Huang et al. (25) suggested that there may be both positively and negatively acting regions in the CT of the PTH/PTH-RP receptor. The results from the
current study, targeted at determining a possible role for individual
serines in the GIP receptor for sequestration, revealed that although
their mutation had little effect on IC50 values or the
level of receptor expression, mutation of serine residues 426 or 427 to
alanine, singly or in combination, resulted in decreased initial rates
of internalization. This is in agreement with the truncation
experiments, in which removal of serines in the CT by chain termination
reduced receptor internalization. Because the level of reduction in
sequestration was greatest with the complete receptor knockout, other
serines, such as amino acid 440, may also play a role. In contrast to
the finding of Tseng and Zhang (37), that substitution of alanine for
cysteine 411 ablated rat GIP receptor desensitization in L293 cells
resulting from 24 h of incubation with ligand, this mutation was
found to have no effect on receptor internalization.
In conclusion, the current studies demonstrated that the majority of
the GIP receptor CT is not required for signaling but that a minimum
chain length of approximately 405 amino acids is needed for receptor
expression. Specific serine residues within the CT, particularly
serines 426 and 427, play an important role in regulating the rate of
receptor internalization.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Xinfang Li and Cuilan Nian for expert technical assistance with the studies described in this manuscript.
| |
FOOTNOTES |
|---|
* The studies were funded by Grants MT-12898 (to M. B. W.) and 590007 (to R. A. P. and C. H. S. M.) from the Canadian Medical Research Council and by the Canadian Diabetes Association (to C. H. S. M. and R. A. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Current address: Dept. of Molecular Signalling, Hagedorn Research Institute, Niels Steensens Vej 6, DK-2820 Gentofte, Denmark.
To whom correspondence should be addressed: Dept. of
Physiology, Faculty of Medicine, University of British Columbia, 2146 Health Sciences Mall, Vancouver V6T 1Z3, British Columbia, Canada. E-mail: mcintoch@unixg.ubc.ca.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; NIDDM, non-insulin-dependent diabetes mellitus; CT, carboxyl-terminal tail; VIP, vasoactive intestinal peptide; PTH, parathyroid hormone; PTH-RP, PTH-related peptide; DMEM, Dulbecco's modified Eagle's medium; BB, binding buffer.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Nauck, M., Stöckman, R., Ebert, R., and Creutzfeldt, W. (1986) Diabetologia 29, 46-52[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Holst, J. J., Gromada, J., and Nauck, M. A. (1997) Diabetologia 40, 984-986[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Nauck, M. A., Heimsaat, M. M., Ørskov, C., Holst, J. J., Ebert, R., and Creutzfeldt, W. (1996) J. Clin. Invest. 91, 301-307 |
| 4. | Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., and Bonner, T. I. (1993) Endocrinology 133, 2861-2870[Abstract] |
| 5. | Wheeler, M. B., Gelling, R. W., McIntosh, C. H. S., Georgiou, J., Brown, J. C., and Pederson, R. A. (1995) Endocrinology 136, 4629-4639[Abstract] |
| 6. | Gremlich, S., Porret, A., Hani, E. H., Cherif, D., Vionnet, N., Froguel, P., and Thorens, B. (1995) Diabetes 44, 1202-1208[Abstract] |
| 7. |
Jelinek, L. J.,
Lok, S.,
Rosenberg, G. B.,
Smith, R. A.,
Grant, F. J.,
Biggs, S.,
Bensch, P. A.,
Kuijper, J. L.,
Sheppard, P. O.,
Sprecher, C. A.,
O'Hara, P. J.,
Foster, D.,
Walker, K. M.,
Chen, L. H. J.,
McKernan, P. A.,
and Kindsvogel, W.
(1993)
Science
259,
1614-1616 |
| 8. |
Thorens, B.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
8641-8645 |
| 9. | Ishahara, T., Nakamura, S., Kaziro, Y., Takahashi, K., and Nagata, S. (1991) EMBO J. 10, 1635-1641[Medline] [Order article via Infotrieve] |
| 10. |
Sreedharan, S. P.,
Robichon, A.,
Peterson, K. E.,
and Goetzl, E. J.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4986-4990 |
| 11. |
Jüppner, H.,
Abou-Samra, A.-B.,
Freeman, M.,
Kong, X. F.,
Shipani, E.,
Richards, J.,
Kolakowski, L. F., Jr.,
Hock, J.,
Potts, J. T., Jr.,
Kronenberg, H. M.,
and Segre, G. V.
(1991)
Science
254,
1024-1026 |
| 12. |
Lin, H. Y.,
Harris, T. L.,
Flannery, M. S.,
Aruffo, A.,
Kaji, E. H.,
Gorn, A.,
Kolakowski, L. F., Jr.,
Lodish, H. F.,
and Goldring, S. R.
(1991)
Science
254,
1022-1024 |
| 13. | Moens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipileers, D., Gremlich, S., Thorens, B., and Schuit, F. (1996) Diabetes 45, 257-261[Abstract] |
| 14. | Amiranoff, B., Vauclin-Jacques, N., and Laburthe, M. (1984) Biochem. Biophys. Res. Commun. 123, 671-676[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Maletti, M., Altman, J. J., Hoa, D. H. B., Carlquist, M., and Rosselin, G. (1987) Diabetes 36, 1336-1340[Abstract] |
| 16. | Lu, M., Wheeler, M. B., Leng, X.-H., and Boyd, A. E., II (1993) Endocrinology 132, 94-100[Abstract] |
| 17. |
O'Dowd, B. F.,
Hnatowich, M.,
Regan, J. W.,
Leader, W. M.,
Caron, M. G.,
and Lefkowitz, R. J.
(1988)
J. Biol. Chem.
263,
15985-15992 |
| 18. |
Liggett, S. B.,
Caron, M. G.,
Lefkowitz, R. J.,
and Hnatowich, M.
(1991)
J. Biol. Chem.
266,
4816-4821 |
| 19. | Hedin, K. E., Duerson, K., and Clapham, D. E. (1983) Cell. Signal. 5, 505-518 |
| 20. |
Burstein, E. S.,
Spalding, T. A.,
Hill-Eubanks, D.,
and Brann, M. R.
(1995)
J. Biol. Chem.
270,
3141-3146 |
| 21. | Takhar, S., Gyomorey, S., Su, R.-C., Mathi, S. K., Li, X., and Wheeler, M. B. (1996) Endocrinology 137, 2175-2177[Abstract] |
| 22. |
Mathi, S. K.,
Chan, Y.,
Li, X.,
and Wheeler, M. B.
(1997)
Mol. Endocrinol.
11,
424-432 |
| 23. | Reneke, J. E., Blumer, K. J., Courchesne, W. E., and Thorner, J. (1988) Cell 55, 221-234[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Hausdorf, W., Caron, M., and Lefkowitz, R. (1990) FASEB J. 4, 2881-2889[Abstract] |
| 25. |
Huang, Z.,
Chen, Y.,
and Nissenson, R. A.
(1995)
J. Biol. Chem.
270,
151-156 |
| 26. | Buggy, J. J., Heurich, R. O., MacDougall, M., Kelley, K. A., Livingston, J. N., Yoo-Warren, H., and Rossomando, A. J. (1997) Diabetes 46, 1400-1405[Abstract] |
| 27. |
Parker, E.,
and Ross, E.
(1991)
J. Biol. Chem.
266,
9987-9996 |
| 28. | Huang, Z., Chen, Y., Pratt, S., Chen, T.-H., Bambino, T., Sholback, D. M., and Nissenson, R. A. (1995) Mol. Endocrinol. 9, 1240-1249[Abstract] |
| 29. |
Iida-Klein, A.,
Guo, J.,
Xie, L. Y.,
Jüppner, H.,
Potts, J. T., Jr.,
Kronenberg, H. M.,
Bringhurst, F. R.,
Abou-Samra, A. B.,
and Segre, G. V.
(1995)
J. Biol. Chem.
270,
8458-8465 |
| 30. | Findlay, D. M., Houssami, S., Lin, H. Y., Myers, D. E., Brady, C. L., Darcy, P. K., Ikeda, K., Martin, T. J., and Sexton, P. M. (1994) Mol. Endocrinol. 8, 1691-1700[Abstract] |
| 31. |
Unson, C. G.,
Cypess, A. M.,
Kim, H. N.,
Goldsmith, P. K.,
Carruthers, C. J. L.,
Merrifield, R. B.,
and Sakmar, T. P.
(1995)
J. Biol. Chem.
270,
27720-27727 |
| 32. |
Widmann, C.,
Dolci, W.,
and Thorens, B.
(1997)
Mol. Endocrinol.
11,
1094-1102 |
| 33. |
Gelling, R. W.,
Wheeler, M. B.,
Xue, J.,
Gyomorey, S.,
Nian, C.,
Pederson, R. A.,
and McIntosh, C. H. S.
(1997)
Endocrinology
138,
2640-2643 |
| 34. |
Kallal, L.,
Gagnon, A. W.,
Penn, R. B.,
and Benovic, J. L.
(1998)
J. Biol. Chem.
273,
322-328 |
| 35. |
Petrou, C.,
Chen, L.,
and Tashjian, A. H., Jr.
(1997)
J. Biol. Chem.
272,
2326-2333 |
| 36. | Böhm, S. K., Grady, E. F., and Bunnett, N. W. (1997) Biochem. J. 322, 1-18 |
| 37. | Tseng, C.-C., and Zhang, X.-Y. (1998) Mol. Cell. Endocrinol. 139, 179-186[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Schneider, H., Feyen, J. H. M., and Seuwen, K. (1994) FEBS Lett. 351, 281-285[CrossRef][Medline] [Order article via Infotrieve] |
| 39. |
Chazenbalk, G. D.,
Nagayama, Y.,
Russo, D.,
Wadsworth, H. L.,
and Rapaport, B.
(1990)
J. Biol. Chem.
265,
20970-20975 |
| 40. | Rodriguez, M. C., Xie, Y.-B., Wang, H., Collison, K., and Segaloff, D. L. (1992) Mol. Endocrinol. 6, 327-336[Abstract] |
| 41. | Nygaard, S. C., Kuestner, R. E., Moore, E. E., and Stroop, S. D. (1997) J. Bone Min. Res. 12, 1681-1690 |
| 42. | Strader, C. D., Fong, T. M., Tota, M. R., Underwood, D., and Dixon, R. (1994) Annu. Rev. Biochem. 63, 101-132[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
C. Parthier, M. Kleinschmidt, P. Neumann, R. Rudolph, S. Manhart, D. Schlenzig, J. Fanghanel, J.-U. Rahfeld, H.-U. Demuth, and M. T. Stubbs Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor PNAS, August 28, 2007; 104(35): 13942 - 13947. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Deacon, A. Plamboeck, M. M. Rosenkilde, J. de Heer, and J. J. Holst GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E468 - E475. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Estall, J. A. Koehler, B. Yusta, and D. J. Drucker The Glucagon-like Peptide-2 Receptor C Terminus Modulates {beta}-Arrestin-2 Association but Is Dispensable for Ligand-induced Desensitization, Endocytosis, and G-protein-dependent Effector Activation J. Biol. Chem., June 10, 2005; 280(23): 22124 - 22134. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Hinke, K. Hellemans, and F. C. Schuit Plasticity of the {beta} cell insulin secretory competence: preparing the pancreatic {beta} cell for the next meal J. Physiol., July 15, 2004; 558(2): 369 - 380. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Marie, C. Rouyer-Fessard, A. Couvineau, P. Nicole, H. Devaud, J. E. Benna, and M. Laburthe Serine 447 in the Carboxyl Tail of Human VPAC1 Receptor Is Crucial for Agonist-Induced Desensitization but Not Internalization of the Receptor Mol. Pharmacol., December 1, 2003; 64(6): 1565 - 1574. [Abstract] [Full Text] [PDF] |
||||